This reduces the risk of ovarian cancer by up to 95% in carriers of pathogenic variants [8], may reduce the risk of breast cancer (BRCA2) [9, 10] and reduces breast/ovarian/all-cause mortality [11]. This evidence concerns the gene BRCA2 and ovarian carcinoma.